Welcome to our dedicated page for Iradimed SEC filings (Ticker: IRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The iRadimed Corporation (IRMD) SEC filings page on Stock Titan aggregates the company’s official disclosures filed with the U.S. Securities and Exchange Commission. These documents provide structured detail on financial performance, governance, and material events related to iRadimed’s business of MRI-compatible medical devices, including non-magnetic IV infusion pump systems and MRI-compatible patient vital signs monitoring systems.
Among the key filings are Form 8-K current reports, which iRadimed uses to announce events such as quarterly financial results, changes in its Board of Directors, and outcomes of stockholder meetings. For example, Form 8-K filings have reported record quarterly revenue, the use of non-GAAP financial measures like non-GAAP net income and free cash flow, the completion of a new facility in Orlando, Florida, and the retirement and appointment of directors. Other 8-Ks furnish press releases that detail FDA 510(k) clearance for the MRidium 3870 IV Infusion Pump System and summarize voting results from the Annual Meeting of Stockholders.
Filings also disclose listing information for iRadimed’s common stock, including its trading symbol IRMD and its listing on the NASDAQ Global Market, with one filing referencing the NASDAQ Capital Market. Governance-related sections describe board committee assignments, independence determinations, and advisory votes on executive compensation. These documents collectively give insight into how the company is overseen and how major decisions are communicated to investors.
On Stock Titan, iRadimed’s SEC filings are paired with AI-powered summaries that explain the contents of lengthy documents in plain language. Users can quickly see the main points of quarterly earnings announcements, board changes, and stockholder votes without reading every page. Real-time updates from EDGAR ensure that new 8-Ks and other filings appear promptly, while AI-generated highlights help readers identify sections related to financial condition, risk factors, and corporate actions. For those researching IRMD’s regulatory history and ongoing obligations, this page offers a focused view of its official SEC reporting.
IRADIMED CORPORATION reported solid growth for the quarter ended September 30, 2025, with revenue of $21.2 million, up 16% year over year. Net income was $5.6 million and diluted EPS was $0.43. Gross margin improved to 78% as device sales led results, including MRI-compatible IV infusion pumps at $8.3 million and patient monitoring systems at $6.9 million. U.S. revenue grew 19% to $18.1 million, while international revenue was $3.1 million.
Operating income rose to $6.8 million as operating expenses increased with higher sales activity and payroll. Cash and cash equivalents were $56.5 million, and contract liabilities rose to $6.7 million, reflecting growth in maintenance agreements and advance customer payments. The company completed its new Orlando facility and announced FDA 510(k) clearance for the next‑generation MRidium 3870, with an initial rollout planned in Q4 2025. The Board declared a regular cash dividend of $0.17 per share, payable November 25, 2025 to holders of record on November 14, 2025. Shares outstanding were 12,721,156 as of October 31, 2025.
IRADIMED (IRMD) insider activity: CEO/President/Chairman and 10% owner Roger E. Susi filed a Form 4 reporting open‑market sales on 10/27/2025 pursuant to a Rule 10b5‑1 trading plan adopted on June 16, 2025.
The filing shows three sales by an indirect holder: 4,242 shares at a weighted average price of $77.56, 700 shares at $78.33, and 58 shares at $79.12. Following these transactions, 2,327,500 shares were beneficially owned indirectly by the Phillip Susi 2008 Dynasty Trust. Additional indirect holdings listed include 162,950 shares by the Roger E. Susi Revocable Trust and 2,062,500 shares by the Matthew Susi 2008 Dynasty Trust, with a stated disclaimer of beneficial ownership except to the extent of pecuniary interest.
IRADIMED Corp (IRMD) insider Roger E. Susi (CEO, President, Chairman, Director, 10% owner) reported open-market sales totaling 5,000 shares of common stock on 10/21/2025, executed under a Rule 10b5-1 trading plan adopted on June 16, 2025.
The filing shows two trades: 3,577 shares at a weighted average price of $74.58 (individual trades ranged $74.17–$75.07) and 1,423 shares at a weighted average price of $75.41 (ranged $75.22–$75.51).
Following the transactions, the report lists 2,332,500 shares indirectly held by the Phillip Susi 2008 Dynasty Trust, 162,950 shares indirectly held by the Roger E. Susi Revocable Trust, and 2,062,500 shares indirectly held by the Matthew Susi 2008 Dynasty Trust. The reporting person disclaims beneficial ownership except to the extent of his pecuniary interest.
IRADIMED Corporation (IRMD) director reported RSU vesting and conversion. On 10/14/2025, 1,767 restricted stock units converted into 1,767 shares of common stock at $0 (Transaction Code M). Following the transaction, the director directly holds 6,496 shares.
The RSUs were granted on 10/14/2022 under the 2014 Equity Incentive Plan and vest in three equal annual installments beginning 10/14/2023, delivering one share for each unit that vests.
IRadimed Corp (IRMD) CEO, President and Chairman Roger E. Susi reported insider sales on 10/13/2025 under a Rule 10b5-1 trading plan adopted on June 16, 2025. The transactions totaled 5,000 shares across three trades: 3,227 shares at a weighted average $72.16 (range $71.65–$72.50), 1,746 shares at $73.37 (range $72.93–$73.86), and 27 shares at $74.07 (range $74.05–$74.15).
Following these sales, indirect beneficial ownership was reported as 2,337,500 shares by the Phillip Susi 2008 Dynasty Trust, 162,950 shares by the Roger E. Susi Revocable Trust, and 2,062,500 shares by the Matthew Susi 2008 Dynasty Trust.
Roger E. Susi, who serves as CEO, President, Chairman and is reported as a 10% owner of Iradimed Corp (IRMD), reported sales of company common stock on
Joe E. Kiani, a director of Iradimed Corporation (IRMD), received a grant of 2,095 restricted stock units (RSUs) on 09/23/2025 under the companys 2023 Equity Incentive Plan. Each RSU represents a contingent right to one share of common stock and the reporting person is shown as directly owning 2,095 shares following the transaction. The RSUs carry a $0 price and vest in three equal annual installments beginning on 09/23/2026, at which time vested units will convert into an equivalent number of common shares. The Form 4 is signed by Joe E. Kiani on 09/25/2025.
Roger E. Susi, CEO, President and Chairman of IRADIMED CORP (IRMD) reported a sale of 5,000 shares of the company on 09/23/2025 under a Rule 10b5-1 trading plan adopted on 06/16/2025. The weighted average sale price was $71.2581, with individual trade prices ranging from $70.81 to $71.61. After the transaction the filing reports total beneficial ownership of 2,352,500 shares, held indirectly through family and revocable trusts; two other trust positions of 162,950 and 2,062,500 shares are disclosed. The reporting person disclaims beneficial ownership except to the extent of pecuniary interest. The Form 4 is signed and dated 09/24/2025.
Roger E. Susi, CEO, President and Chairman of IRADIMED CORP (IRMD), reported sales of common stock on 09/17/2025 under a Rule 10b5-1 trading plan adopted 06/16/2025. The filing shows 3,454 shares sold at a weighted average price of $71.0016 and 1,546 shares sold at a weighted average price of $71.8808, executed in multiple trades with price ranges disclosed. After these dispositions, aggregate beneficial ownership reported across related trusts and accounts totals 2,062,500 shares directly and 2,359,046/2,357,500 shares indirectly as stated, with a disclaimer limiting claimed beneficial ownership. The form is signed 09/18/2025.
FAQ
What is the current stock price of Iradimed (IRMD)?
What is the market cap of Iradimed (IRMD)?
